Journal of Neuro-Oncology

, Volume 117, Issue 3, pp 485–491 | Cite as

Endocan, a new invasion and angiogenesis marker of pituitary adenomas

  • Fumihiro MatanoEmail author
  • Daizo Yoshida
  • Yudo Ishii
  • Shigeyuki Tahara
  • Akira Teramoto
  • Akio Morita
Clinical Study


Angiogenesis plays a crucial role in tumor growth. Recently, endocan has emerged as a new marker of vascular endothelial cells from cancers in other organs. In this study, we elucidated the relationship between endocan expression and tumor invasion of pituitary adenoma. Tumor tissues were obtained from 70 patients with pituitary adenoma and were examined using fluorescence immunohistochemistry. Tissue samples included 4 adrenocorticotrophic hormone producing adenomas, 10 growth hormone-producing adenomas, 49 clinically nonfunctioning adenomas, 6 prolactin producing adenomas, and 1 thyroid-stimulating hormone producing adenoma. Endocan was exclusively expressed in CD34-positive vascular endothelial cells, with over 90 % colocalization. The CD34 expression was significantly elevated with endocan expression (linear regression slope, 1.200; r2 = 0.268, F = 23.08, p < 0.0001). As a percentage of CD34 expression, endocan expression was elevated in a Knosp grading dependent manner (Spearman’s r-value, 0.651; p < 0.0001), and was also significantly elevated in macroadenomas compared with microadenomas (p = 0.0133). However, no differences in endocan expression were observed between hormonal subtypes (p = 0.066; Kruskal–Wallis test), age (Spearman’s rank correlation test, p = 0.4909), or sex (Mann–Whitney test, p = 0.1701). These data show that endocan is closely related to tumor angiogenesis, and may predict tumor invasion into neighboring cavernous sinuses in pituitary adenomas.


Endocan Vascular endothelial cell Tumor angiogenesis Tumor invasion 



This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan (Nos. 20591726 and 18390405).

Conflict of interest

There are no conflicts of interest for all authors. Fumihiro Matano who is a member of the JNS have registered on-line Self-reported COI Disclosure Statement Forms through the web-site for JNS members.


  1. 1.
    Di Ieva A, Grizzi F, Ceva-Grimaldi G, Aimar E, Serra S, Pisano P, Lorenzetti M, Tancioni F, Gaetani P, Crotti F, Tschabitscher M, Matula C, Rodriguez YBR (2010) The microvascular network of the pituitary gland: a model for the application of fractal geometry to the analysis of angioarchitecture and angiogenesis of brain tumors. J Neurosurg Sci 54:49–54PubMedGoogle Scholar
  2. 2.
    Di Ieva A, Weckman A, Di Michele J, Rotondo F, Grizzi F, Kovacs K, Cusimano MD (2013) Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre. Microvasc Res 89:7–14. doi: 10.1016/j.mvr.2013.04.009 PubMedCrossRefGoogle Scholar
  3. 3.
    Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F (2009) Microvessel density and area in pituitary microadenomas. Endocr Pathol 20:221–226. doi: 10.1007/s12022-009-9091-1 PubMedCrossRefGoogle Scholar
  4. 4.
    Lee JS, Park YS, Kwon JT, Nam TK, Lee TJ, Kim JK (2011) Radiological apoplexy and its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in pituitary adenomas. J Korean Neurosurg Soc 50:281–287. doi: 10.3340/jkns.2011.50.4.281 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Zhang Y, He N, Zhou J, Chen Y (2011) The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. Clin Imaging 35:165–173. doi: 10.1016/j.clinimag.2010.06.002 PubMedCrossRefGoogle Scholar
  6. 6.
    Yamada S, Takada K (2003) Angiogenesis in pituitary adenomas. Microsc Res Tech 60:236–243. doi: 10.1002/jemt.10262 PubMedCrossRefGoogle Scholar
  7. 7.
    Nomura R, Yoshida D, Teramoto A (2009) Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. J Neurooncol 94:173–181. doi: 10.1007/s11060-009-9835-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145. doi: 10.1016/j.mvr.2006.05.010 PubMedCrossRefGoogle Scholar
  9. 9.
    Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12:4575–4582. doi: 10.1158/1078-0432.ccr-06-0185 CrossRefGoogle Scholar
  10. 10.
    Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37. doi: 10.1016/j.bbcan.2005.08.004 PubMedGoogle Scholar
  11. 11.
    Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532–537PubMedCrossRefGoogle Scholar
  12. 12.
    Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22:757–764. doi: 10.1111/j.1750-3639.2012.00578.x PubMedCrossRefGoogle Scholar
  13. 13.
    Filep JG (2006) Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 34:574–575PubMedCrossRefGoogle Scholar
  14. 14.
    Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68:633–641. doi: 10.1097/NEN.0b013e3181a52a7f PubMedCrossRefGoogle Scholar
  15. 15.
    Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P (2007) Endocan is a VEGF-A and PI3 K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. doi: 10.1016/j.yexcr.2007.01.021 PubMedCrossRefGoogle Scholar
  16. 16.
    Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, Wu Q, Wang Y (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol WJG 14:4562–4568CrossRefGoogle Scholar
  17. 17.
    Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54:389–394. doi: 10.1007/s10620-008-0346-3 PubMedCrossRefGoogle Scholar
  18. 18.
    Hatfield KJ, Lassalle P, Leiva RA, Lindas R, Wendelboe O, Bruserud O (2011) Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology (Amsterdam, Netherlands) 16:351–356. doi: 10.1179/102453311x13127324303434 Google Scholar
  19. 19.
    Zhang S, Zuo L, Gui S, Zhou Q, Wei W, Wang Y (2012) Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep 39:2843–2849. doi: 10.1007/s11033-011-1043-4 PubMedCrossRefGoogle Scholar
  20. 20.
    El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y (2013) Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. doi: 10.1007/s00404-013-2863-3 Google Scholar
  21. 21.
    Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, Localio AR, Albelda SM, Meyer NJ, Christie JD (2012) Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 27(522):e511–e527. doi: 10.1016/j.jcrc.2011.07.077 Google Scholar
  22. 22.
    Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y (2012) Expression and distribution of endocan in human tissues. Biotechnic Histochem Off Publ Biol Stain Comm 87:172–178. doi: 10.3109/10520295.2011.577754 CrossRefGoogle Scholar
  23. 23.
    Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, Kurt O, Kurt YG, Aydin I, Kilic S (2013) Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. doi: 10.1111/bjd.12525 PubMedGoogle Scholar
  24. 24.
    De Freitas Caires N, Legendre B, Parmentier E, Scherpereel A, Tsicopoulos A, Mathieu D, Lassalle P (2013) Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 78–79:45–51. doi: 10.1016/j.jpba.2013.01.035 Google Scholar
  25. 25.
    Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N’Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lassalle P, Charnaux N, Delehedde M, Sutton A, Nahon P (2013) Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomark Prev. doi: 10.1158/1055-9965.epi-13-0179 Google Scholar
  26. 26.
    Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M, Otto VI, Detmar M (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73:1097–1106. doi: 10.1158/0008-5472.can-12-1855 PubMedCrossRefGoogle Scholar
  27. 27.
    Pizarro CB, Oliveira MC, Pereira-Lima JF, Leaes CG, Kramer CK, Schuch T, Barbosa-Coutinho LM, Ferreira NP (2009) Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology Off J Jpn Soc Neuropathol 29:40–44. doi: 10.1111/j.1440-1789.2008.00937.x CrossRefGoogle Scholar
  28. 28.
    Yoshida D, Nomura R, Teramoto A (2009) Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol 21:481–488. doi: 10.1111/j.1365-2826.2009.01867.x PubMedCrossRefGoogle Scholar
  29. 29.
    Yoshida D, Koketshu K, Nomura R, Teramoto A (2010) The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells. J Neurooncol 100:51–64. doi: 10.1007/s11060-010-0152-6 PubMedCrossRefGoogle Scholar
  30. 30.
    Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23–28PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Fumihiro Matano
    • 1
    Email author
  • Daizo Yoshida
    • 1
  • Yudo Ishii
    • 1
  • Shigeyuki Tahara
    • 1
  • Akira Teramoto
    • 1
  • Akio Morita
    • 1
  1. 1.Department of NeurosurgeryNippon Medical SchoolTokyoJapan

Personalised recommendations